ArticleNeurocritical care2005
Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation.
Article in Neurocritical care, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Posterior Reversible Encephalopathy Syndrome in the Immediate Postoperative Period of Gastric Cancer.Cureus · 2023Article
- Frequency and Risk Factors of Cyclosporine-Induced Neurotoxicity in Allogeneic Stem Cell Transplant Recipients.Cureus · 2021Article
- Cyclosporine A-related neurotoxicity after haploidentical hematopoietic stem cell transplantation in children with hematopathy.Italian journal of pediatrics · 2021Article
- Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome: Clinical and Radiological Considerations.Frontiers in neurology · 2020Review
- Posterior Reversible Encephalopathy Syndrome: Clinical Features and Outcome.Frontiers in neurology · 2020Review
- Reversible posterior leukoencephalopathy associated with chronic graft-versus-host disease: A case report.Experimental and therapeutic medicine · 2016Article
- A 16 Month Survey of Cyclosporine Utilization Evaluation in Allogeneic Hematopoietic Stem Cell Transplant Recipients.Iranian journal of pharmaceutical research : IJPR · 2016Article
- Childhood posterior reversible encephalopathy syndrome: Magnetic resonance imaging findings with emphasis on increased leptomeningeal FLAIR signal.The neuroradiology journal · 2015Article
- Posterior Reversible Encephalopathy Syndrome in Patients With Cancer.The oncologist · 2015Article
- High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome.Italian journal of pediatrics · 2010Article
- Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features.AJNR. American journal of neuroradiology · 2009Article
- Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.AJNR. American journal of neuroradiology · 2008Review
- Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.AJNR. American journal of neuroradiology · 2008Review
- Posterior reversible encephalopathy syndrome after solid organ transplantation.AJNR. American journal of neuroradiology · 2008Article
- Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome.AJNR. American journal of neuroradiology · 2008Article
- Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome.AJNR. American journal of neuroradiology · 2007Article
- Posterior reversible encephalopathy syndrome in infection, sepsis, and shock.AJNR. American journal of neuroradiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study examines whether malignant disease under treatment influences the incidence of cyclosporine or FK-506 neurotoxicity after myeloablative conditioning and allogeneic bone marrow transplantation (allo-BMT).
methodsReview of 290 patients who received myeloablative conditioning prior to allo-BMT and cyclosporine/FK-506 identified 21 (7.2%) patients with neurotoxicity confirmed by computed tomography or magnetic resonance. Underlying malignancy necessitating allo-BMT included leukemias (67%), lymphoma (10%), myelodysplastic syndrome (10%), and multiple myeloma (MM). Frequency of neurotoxicity by disease was compared.
resultsThe highest incidence of neurotoxicity was present with MM (25%), whereas the lowest incidence was present with lymphoma (2.7%). Other diseases demonstrated intermediate incidence, including acute leukemias (10%), myelodysplastic syndrome (6.4%), and chronic myelogenous leukemia (4.9%).
conclusionCyclosporine/FK-506 neurotoxicity varied according to the underlying malignancy. The variable susceptibility to the development of neurotoxicity in this population may depend on the interaction of host vasculature with disease specific factors. Understanding the cause of neurotoxicity could improve survival after allo-BMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.